In Vivo Accumulation of Regulatory T Cells Using Eliglustat-Loaded Cryogels.

Vitner, Einat B; Bovone, Giovanni; Jung, Wei-Hung; Lou, Junzhe; Hankenson, Hugh; Dacus, Mason T; Binenbaum, Yoav; Adu-Berchie, Kwasi et al. · Adv Healthc Mater · 2025

basic_science · Level V

Where this comes from

Abstract

Regulatory T cells (T<sub>regs</sub>) maintain immune homeostasis and their adoptive transfer is being widely explored to mitigate inflammatory and autoimmune conditions. Here a biomaterial is developed to accumulate T<sub>regs</sub> at a specific anatomic location to bypass the need for ex vivo T<sub>reg</sub> isolation and adoptive transfer. It is first shown that eliglustat, an FDA-approved inhibitor of UDP-glucose ceramide glucosyltransferase, promotes T<sub>regs</sub> from both naïve and activated CD4<sup>+</sup> T cells in vitro. Click-crosslinked cryogels fabricated from alginate and collagen allow for a sustained release of CXCL10 or CXCL11, and when injected in subcutaneous tissues led to the enrichment of effector and memory T cells to the scaffolds. Loading eliglustat into these cryogels significantly enhances the local accumulation of T<sub>regs</sub> in vivo. These findings demonstrate that eliglustat-loaded cryogels offer a simple yet effective biomaterial strategy to boost T<sub>reg</sub> directly in vivo, potentially providing a targeted method to treat various inflammatory and autoimmune diseases.

Medical subject headings